{"id":"sars-cov-2-rs-matrix-m1-adjuvant","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4650407","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine works by introducing the SARS-CoV-2 spike protein and Matrix M1 adjuvant to the body, which triggers an immune response and helps the body recognize and fight the virus. The Matrix M1 adjuvant enhances the immune response by activating immune cells and increasing the production of antibodies.","oneSentence":"SARS-CoV-2 rS/Matrix M1-Adjuvant is a vaccine that uses the SARS-CoV-2 spike protein and Matrix M1 adjuvant to stimulate an immune response against SARS-CoV-2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:30.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT07079670","phase":"PHASE3","title":"Safety and Immunogenicity of NVX-CoV2705","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":676},{"nctId":"NCT07086222","phase":"PHASE4","title":"Efficacy and Safety of NVX-CoV2705","status":"NOT_YET_RECRUITING","sponsor":"Novavax","startDate":"2025-11-10","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":6500},{"nctId":"NCT06409663","phase":"PHASE3","title":"A Strain Change Study for SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2024-10-14","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 Infection","enrollment":60},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05973006","phase":"PHASE3","title":"Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-08-16","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05875701","phase":"PHASE3","title":"Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-03-28","conditions":"COVID-19","enrollment":147},{"nctId":"NCT04583995","phase":"PHASE3","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-09-28","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":15185},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT04961541","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2021-09-08","conditions":"SARS-CoV Infection, Covid19","enrollment":637},{"nctId":"NCT06482359","phase":"PHASE2, PHASE3","title":"Lot Consistency Study of COVID-19 and Influenza Combination Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2025-02-01","conditions":"COVID-19, Influenza","enrollment":""},{"nctId":"NCT05468736","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2022-07-22","conditions":"COVID-19","enrollment":3600},{"nctId":"NCT05925127","phase":"PHASE2, PHASE3","title":"Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-10-16","conditions":"COVID-19","enrollment":994},{"nctId":"NCT05519839","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-12-30","conditions":"COVID-19, Influenza","enrollment":1579},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT05975060","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-09-07","conditions":"COVID-19","enrollment":660},{"nctId":"NCT05372588","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-05-25","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":1340},{"nctId":"NCT04611802","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-12-27","conditions":"SARS-CoV Infection, Covid19","enrollment":33000},{"nctId":"NCT05249816","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine","status":"COMPLETED","sponsor":"Cogna Technology Solutions LLC","startDate":"2022-03-18","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":1000},{"nctId":"NCT05463068","phase":"PHASE3","title":"Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-07-11","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":911},{"nctId":"NCT04368988","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-05-25","conditions":"COVID-19","enrollment":1419},{"nctId":"NCT05112848","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-02-28","conditions":"SARS-CoV-2 Infection","enrollment":384},{"nctId":"NCT04533399","phase":"PHASE2","title":"A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-08-17","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":4422}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NVX-CoV2373"],"phase":"phase_3","status":"active","brandName":"SARS-CoV-2 rS/Matrix M1-Adjuvant","genericName":"SARS-CoV-2 rS/Matrix M1-Adjuvant","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"SARS-CoV-2 rS/Matrix M1-Adjuvant is a vaccine that uses the SARS-CoV-2 spike protein and Matrix M1 adjuvant to stimulate an immune response against SARS-CoV-2. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}